Show simple item record

dc.contributor.authorHussain, A.
dc.contributor.authorLee, R.J.
dc.contributor.authorGraff, J.N.
dc.date.accessioned2019-08-05T17:00:32Z
dc.date.available2019-08-05T17:00:32Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85066431295&doi=10.1016%2fj.critrevonc.2019.04.020&partnerID=40&md5=2bc6747d3a7777c35fa9ca5f552b0b52
dc.identifier.urihttp://hdl.handle.net/10713/10236
dc.description.abstractBone metastases are a frequent complication of solid tumors, leading to significant skeletal sequelae that negatively impact quality of life and survival. Prevention and management of skeletal-related complications are critical treatment goals in oncology. Endpoints used in clinical trials to evaluate skeletal-related complications have evolved. In contrast to single measures of bone health, contemporary clinical trial endpoints reflect composite measures of skeletal-related complications, and increasingly also survival. In addition, key symptomatic components, which are more reflective of quality of life and the patient experience, are being incorporated. Given the evolution and resulting diversity of the endpoints being used in pivotal trials, it is becoming increasingly relevant to clarify the utility and the potential clinical impact of these measures not only within the context of trials but also in the real-world setting. Here, we describe the development and evolution of skeletal endpoints used in trials, and discuss their clinical relevance. Copyright 2019 The Authorsen_US
dc.description.sponsorshipPart of AH's time was supported by a Merit Review Award (I01 BX000545), Medical Research Service, Department of Veterans Affairs .en_US
dc.description.urihttps://doi.org/10.1016/j.critrevonc.2019.04.020en_US
dc.language.isoen-USen_US
dc.publisherElsevier Ireland Ltden_US
dc.relation.ispartofCritical Reviews in Oncology/Hematology
dc.subjectBoneen_US
dc.subjectBone metastasesen_US
dc.subjectEndpointen_US
dc.subjectSkeletal-related eventen_US
dc.subjectSymptomatic skeletal eventen_US
dc.titleThe evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the boneen_US
dc.typearticleen_US
dc.identifier.doi10.1016/j.critrevonc.2019.04.020
dc.identifier.pmid31170574


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record